Prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis

摘要

BACKGROUND:This study aimed to investigate the prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC).METHODS:We retrospectively analyzed the medical records of patients with newly diagnosed SCLC who had received first-line chemotherapy at the Department of Pulmonary Oncology of the PLA 307 Hospital between January 2008 and October 2018. The optimal cutoff value of the continuous variables was determined using the X-tile software. Univariate and multivariate analyses were conducted using Cox proportional hazard models. The Kaplan-Meier method was used for survival analysis, with differences tested using the log-rank test.RESULTS:A total of 146 patients were included. The cutoff value for HRR was determined as 0.985. Statistically significant differences were observed in sex, smoking history, stage, radiotherapy combination, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, hemoglobin, and red blood cell distribution width between the high and low HRR groups. The median overall survival (OS) was nine and 17.5 months in the low and high HRR groups, respectively (P??0.001). The median progression-free survival (PFS) was five and 8.5 months, respectively (P??0.001). Univariate and multivariate analyses showed low HRR to be an independent predictor of a poor prognosis for OS (hazard ratio = 3.782; 95% confidence interval, 2.151-6.652; P??0.001) and PFS (hazard ratio = 2.112; 95% confidence interval, 1.195-3.733; P = 0.01) in SCLC.CONCLUSION:Low HRR was associated with poorer OS and PFS in patients with SCLC and can be a potentially valuable prognostic factor for these patients.KEY POINTS:The prognostic value of the baseline hemoglobin-to-red blood cell distribution width ratio was evaluated in patients with small cell lung cancer. In this population, this ratio was an independent predictor of overall survival and progression-free survival. This ratio, an inexpensive and routine parameter, can be used as a prognostic factor in small cell lung cancer.? 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.